Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06300424 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC

Study acronym: NEOVADE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruitingv4 Show 4 more changesShow less
    • Primary completion date changed from estimate of Mar 2026 to Jan 26, 2026
    • Study completion date: Sep 2027 to Apr 30, 2026
    • Start date changed from estimate of Apr 2024 to Apr 1, 2024
    • Site details revised
  2. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v3
  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Phase II, single-arm, open-label study that assess clinical feasibility and safety of neoadjuvant almonertinib followed by 3 cycles neoadjuvant adebrelimab plus chemotherapy in EGFR-mutant stage IIA-IIIB NSCLC followed by surgery, adjuvant treatment was upon investigators' decisions.
Trial Details
NCT Number NCT06300424
Lead Sponsor Guangdong Provincial People's Hospital
Conditions
(from sponsor)		 Non Small Cell Lung Cancer, EGFR Gene Mutation
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov